Logo

05- CV Hafid Ait Oufella

Hafid AIT-OUFELLA

University Professor and Hospital Practitioner – PU-PH
Team Leader – Immuno-Metabolic Mechanisms of Cardioavascular Diseases
Mail: hafid.aitoufella@inserm.fr
Phone: +33 6 12 01 19 40

 

SCIENTIFIC TOPICS

  • Atherosclerosis
  • Myocardial infarction
  • Aneurysm
  • Immunity
  • Inflammation
  • Metabolism

ITMO

  • Physiopathologie, métabolisme, nutrition

Biosketch

Trained as a cardiologist, I am currently University Professor and Hospital Practitioner in a medical intensive care unit at Hôpital Saint-Antoine. I share my time between care and clinical research on the one hand, and experimental research on the other. Since 2002, I have developed a fundamental research activity on the exploration and modulation of the immune response in cardiovascular diseases. During my PhD, I explored the role of regulatory T cells and efferocytosis in atherosclerosis development under the supervision of Ziad Mallat (Ait-Oufella et al. Nat Med 2006, Circulation 2007 & 2007). During my post-doc, I studied the role of B cells in atherosclerosis (Ait-Oufella et al. J Exp Med 2009) in the Inserm unit U689. In 2010, I joined the Inserm unit U970, at PARCC-HEGP institute, where I developed and supervised new independent research projects  focusing on the role of immune system in the pathophysiology of atherosclerosis (Joffre et al. JACC 2016, Zeboudj et al. JACC 2018, Zhang et al Nat Commun 2023), post-ischemic cardiac remodeling (Zouggari et al. Nat Med 2013, Santos-Zas et al. Nat Commun 2021) and aortic aneurysm (Giraud et al. Cardiovasc Res 2015; Vandestienne et al JCI 2021, Al-Rifai et al. Nat Commun 2022). Since January 2020 I am heading the Team 5 “Immuno-metabolic mechanisms of cardiovascular diseases”. Using genetically-modified mouse models and human tissue biobanks, I aim to improve our understanding of the pathophysiology of heart and vascular diseases, and to develop new therapeutic approaches targeting innate and/or adaptive immunity.

Academic position

  • 2021 – now: CSO & CMO POLYGON Therapeutics

  • 2019 – now: Head Inserm U970 Team 5 “Immuno-metabolic mechanism of cardiovascular diseases”, Paris, France

  • 2014 – now: Professor of Medicine, Division of Intensive Care Medicine, St-Antoine Hospital, Paris

  • 2010 – 2014: Associate Professor of Medicine, Division of Intensive Care Medicine, St-Antoine Hospital

Responsabilities and activities

 
  • 2010 – date: Scientific Reviewer for sereval peer-reviewed journals (J Clin Invest, J Exp Med, PNAS, Circulation, Nature Communications, Intensive Care Medicine, ATVB)

  • 2012 – 2016: Member of the scientific commission of Inserm CSS4 « Physiologie et physiopathologie des systèmes cardiaque, vasculaire, pulmonaire, néphrologie et musculaire »

  • 2014 – Date: Scientific Evaluation for several national and international organizations (British Heart Foundation, Austrian Heart Foundation, Netherlands Organization for Health Research and Development, Swiss National Foundation.)

  • 2014 – Date: External evaluator of PhDs in several European countries (France, UK, Sweden, Germany, etc.)

Awards

  • 2022     Prix de l’académie nationale de médecine
  • 2021     Prix de Recherche fondamentale de l’association Robert Debré
  • 2020     Outstanding Achievement Award (European Society of Cardiology)
  • 2019     Prix Alain Castaigne de la Société Française de Cardiologie
  • 2010     Prix de la Chancellerie des Universités, France
  • 2008     Prix René Fauvert, Paris Public Hospitals
  • 2007     Young Investigator award (Eur. Vascular Genomics Network, United Kingdom)
  • 2007     Young Investigator award (International Vascular biology Meeting, The Netherlands)
  • 2006     Young investigator Award (N. Société Française d’Athérosclérose, Biarritz, France)
  • 2000     Silver Medal, Internal Medicine, Paris 

Scientific summary

 

Hafid Ait-Oufella is a clinician scientist who has made major contributions to cardiovascular immunology. He identified critical counter-regulatory immune mechanisms that tame the development and progression of cardiovascular disease such as regulatory T cells. He identified the crucial pathogenic role of B cells in the pathophysiology of atherosclerosis and deleterious post-ischemic cardiac remodeling. He revealed the key role of TREM-1 receptor in both human and experimental atherosclerotic cardiovascular dieases. Hafid Ait-Oufella also undertook innovative research into the pathophysiology of aortic aneurysms, opening new research avenues. He has made sustained and internationally recognized contributions to our understanding of cardiovascular immunology and atherosclerotic diseases and translated these novel findings into new therapeutic monoclonal antibodies approaches.